Rovalpituzumab Tesirine Active in Recurrent Small Cell Lung Cancer

Share this content:
Rovalpituzumab tesirine demonstrated encouraging single-agent antitumor activity with a manageable toxicity profile.
Rovalpituzumab tesirine demonstrated encouraging single-agent antitumor activity with a manageable toxicity profile.

Rovalpituzumab tesirine demonstrated encouraging single-agent antitumor activity with a manageable toxicity profile among patients with recurrent small cell lung cancer (SCLC), according to a study published in The Lancet Oncology.1

Delta-like protein 3 (DLL3) is a novel target identified in tumor-initiating cells, and is expressed in more than 80% of patients with SCLC. Researchers evaluated the activity and safety of rovalpituzumab tesirine, a first-in-class antibody-drug conjugate directed against DLL3, among patients whose disease progressed after 1 or more prior regimens.

For the open-label, phase 1 study (ClinicalTrials.gov Identifier: NCT01901653), researchers enrolled 82 patients with SCLC or large-cell neuroendocrine tumors with progressive disease who previously received 1 to 2 previous regimens, including a platinum-based regimen. Participants received rovalpituzumab tesirine at varying doses every 3 weeks or every 6 weeks.

Dose-limiting toxicities occurred at a dose of 0.8 mg/kg every 3 weeks, including grade 4 thrombocytopenia in the 2 patients that received that dose level and grade 4 liver function test abnormalities in 1 patient. The most common grade 3 or worse treatment-related adverse events in the 74 patients with SCLC were thrombocytopenia (11%), pleural effusion (8%), and increased lipase (7%).

Among those with SCLC, 38% experienced treatment-related serious adverse events.

Eighteen percent of the evaluable 60 patients achieved a confirmed objective response, with a median duration of 5.6 months (95% CI, 2.5-8.3). Thirty-eight percent of 26 patients with confirmed high DLL3 expression achieved a response with a median duration of 4.3 months (95% CI, 2.2-15).

Median progression-free survival was 2.8 months (95% CI, 2.5-4.0) and 4.3 months (95% CI, 2.8-5.6) overall and for patients with high DLL3 expression, respectively.

RELATED: Tumor, Node, and Metastasis Classification: 8th Edition Changes

The findings suggest that further assessment of rovalpituzumab tesirine in DLL3-expressing malignant diseases is warranted.

Reference

  1. Rudin CM, Pietanza MC, Bauer TM, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2016 Dec 5. doi: 10.1016/S1470-2045(16)30565-4 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters